- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01780909
The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit
The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit. Evaluatie Van de Gastrointestinale Transit Aan de Hand Van de Niet-absorbeerbare Merker Paromomycine Sulfaat (Dutch Translation)
Aim of the study The aim of this study is to use Gabbroral® oral tablet formulation as marker for the evaluation of the gastrointestinal transit. By collecting and analyzing both gastric and intestinal fluids on different time points, the transfer dissolution can be distracted. For this study stomach fluid and intestinal fluid will be collected after oral intake of a commercially available dosing form of Paromomycin Sulfate (Gabbroral® oral tablet formulation), which is dissolved in a glas of 240mL water, in fasted or fed state. Four intake conditions will be tested on four different test days (with an intermediate period of at least 7 days).
- intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state.
- intake of Gabbroral® oral tablet formulation in fed state.
- Intake of 2 tablets of Motilium® (API: domperidone 10 mg) 20 minutes before the intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water.
- Intake of 2 tablets of Motilium® (API: loperamide HCl 2 mg) 20 minutes before the intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water.
Conduct of the study
- The study consists of four testing days in the University Hospitals Leuven, Gasthuisberg campus.
- On each test day you come at the agreed time in fasting State to the Gastroenterology Department at UZ Leuven (Gasthuisberg, floor 0, Orange arrow). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water.
- A basic clinical anamnesis will be taken by a doctor to make sure that you are a healthy volunteer for our study. For making sure that you are HIV negative, you will undergo an HIV test. In case of a female volunteer, a pregnancy test will be taken in account to make sure you are not pregnant.
- Upon arrival at the hospital through the nose or the mouth two probes: one in the stomach and one in the gut. The position of both probes is controlled using fluoroscopy (x-ray).
After a stabilisation period of ca. 20 min you will be asked for taking a single dose of Gabbroral® oral tablet formulation. On four different test days, with an intermediate period of at least 7 days, we will follow every one of following intake conditions:
- intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state.
- intake of Gabbroral® oral tablet formulation in fed state.
- Intake of 2 tablets of Motilium® (API: domperidone 10 mg) 20 minutes before the intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water.
- Intake of 2 tablets of Motilium® (API: loperamide HCl 2 mg) 20 minutes before the intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water.
- After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water).
- After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bart Hens, Pharmacist
- Phone Number: +3216330302
- Email: bart.hens@pharm.kuleuven.be
Study Locations
-
-
BE
-
Leuven, BE, Belgium, 3000
- Recruiting
- Gasthuisberg
-
Sub-Investigator:
- Jan Tack, PhD MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers
- age: 20-35 year
Exclusion Criteria:
- Diseases
- Acute/chronic gastrointestinal disorders
- Medication use
- Possible pregnancy
- Frequent exposure to x-ray radiation during the past year
- HIV positive
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paromomycin Sulfate Fasted State
Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state.
Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water.
• After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours.
You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water).
After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
|
Other Names:
|
Experimental: Paromomycin Sulfate Fed State
Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state.
Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water.
When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed.
20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved.
After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours.
You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water).
After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
|
Other Names:
|
Experimental: Paromomycin Sulfate w/ Domperidone
Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg).
Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water.
20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying.
After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours.
You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water).
After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
|
Other Names:
|
Experimental: Paromomycin Sulfate w/ Loperamide HCl
Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg).
Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water.
20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine.
After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours.
You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water).
After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentration-time profiles of the drug paromomycin sulfate in the stomach and intestine
Time Frame: This concentration-time profiles in the stomach and intestine will be measured for 4 hours.
|
This concentration-time profiles in the stomach and intestine will be measured for 4 hours.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Dopamine Agents
- Dopamine Antagonists
- Antiprotozoal Agents
- Antiparasitic Agents
- Paromomycin
- Domperidone
- Loperamide
- Antidiarrheals
Other Study ID Numbers
- DDD13PM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Concentration-Time Profiles in Stomach & Intestine.
-
Mennatallah Mohamed ElnemrUnknownAim is to Investigate Association Between Lactate Concentration in Vaginal Fluid and Time of Spontaneous Onset of Labor in PPROMEgypt
-
Second Affiliated Hospital, School of Medicine,...RecruitingTime in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic GastroparesisChina
-
St. Luke's Hospital and Health Network, PennsylvaniaBoehringer IngelheimUnknownEnhance Delineation of the Stomach Anatomy and the Surgeon's Appreciation of the Extent of Gastric Volume to be Removed; | Increase the Safety Profile of the Patient (i.e., Reduce the Likelihood of Accidental Stapling of the Orogastric Tube or Bougie); | Reduce the Incidence of OR... and other conditionsUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
Clinical Trials on Paromomycin Sulfate Fasted State
-
GlaxoSmithKlineCompleted
-
Daewoong Pharmaceutical Co. LTD.Hanyang UniversityUnknownErosive EsophagitisKorea, Republic of
-
Konkuk University Medical CenterDaewoong Pharmaceutical Co. LTD.RecruitingErosive EsophagitisKorea, Republic of
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Universitaire Ziekenhuizen KU LeuvenCompletedObesity | Bariatric Surgery CandidateBelgium
-
Manchester Metropolitan UniversityEuropean Society for Clinical Nutrition and MetabolismRecruitingCardiovascular Diseases | Obesity | Diabetes Mellitus, Type 2United Kingdom
-
PATHCompletedVisceral LeishmaniasisIndia
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | CryptosporidiosisUnited States, Puerto Rico